Minerva Neurosciences (NERV) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Minerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates
August 5, 2015 7:30 AM EDTOpening of clinical sites in six countries builds momentum in MIN-101 Phase IIb schizophrenia trial
First patient dosed in Phase IIa study with MIN-117 in major depressive disorder
First patient dosed in Phase Ib study with MIN-202 as adjunctive treatment for major depressive disorder; MIN-202 data in insomnia presented at SLEEP meeting
Company adds to Board and management
Management to host conference call today at 8:30 a.m. Eastern Time
WALTHAM, Mass., Aug. 5, 2015 (GLOBE... More
